Marker Therapeutics (NASDAQ:MRKR) Upgraded to Strong-Buy at Brookline Capital Management

Brookline Capital Management upgraded shares of Marker Therapeutics (NASDAQ:MRKR) to a strong-buy rating in a research note published on Monday morning,Zacks.com reports.

Separately, LADENBURG THALM/SH SH raised their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a report on Monday, October 21st.

Marker Therapeutics Stock Performance

MRKR stock opened at $1.55 on Monday. Marker Therapeutics has a fifty-two week low of $1.55 and a fifty-two week high of $5.99. The company’s 50 day moving average price is $2.92 and its 200 day moving average price is $3.25.

Insider Transactions at Marker Therapeutics

In related news, Director Steve Elms purchased 11,085 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average cost of $3.20 per share, with a total value of $35,472.00. Following the completion of the transaction, the director now directly owns 325,370 shares in the company, valued at approximately $1,041,184. The trade was a 3.53 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Enterprise Associates 16 New acquired 554,250 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the purchase, the insider now directly owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. This represents a 51.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 17.35% of the company’s stock.

Institutional Trading of Marker Therapeutics

An institutional investor recently bought a new position in Marker Therapeutics stock. LPL Financial LLC purchased a new position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 79,730 shares of the company’s stock, valued at approximately $248,000. LPL Financial LLC owned 0.74% of Marker Therapeutics as of its most recent SEC filing. 22.39% of the stock is currently owned by hedge funds and other institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.